Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma

Renal-cell carcinoma (RCC) affects over 330,000 new patients every year, of whom 1/3 present with metastatic RCC (mRCC) at diagnosis. Most mRCC patients treated with a first-line agent relapse within 1 year and need second-line therapy. The present study aims to compare overall survival (OS) between...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiecek, Witold, Karcher, Helene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894561/
https://www.ncbi.nlm.nih.gov/pubmed/27271250
http://dx.doi.org/10.1371/journal.pone.0155389

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894561/
https://www.ncbi.nlm.nih.gov/pubmed/27271250
http://dx.doi.org/10.1371/journal.pone.0155389

Ejemplares similares